Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S396000
Reexamination Certificate
active
07960389
ABSTRACT:
Compounds of general formula:wherein R1, R2and R3are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
REFERENCES:
patent: 3940386 (1976-02-01), Szabo et al.
patent: 4778789 (1988-10-01), Fex et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5658908 (1997-08-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5840896 (1998-11-01), Van Belle et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6130222 (2000-10-01), Roberts et al.
patent: 6680318 (2004-01-01), Brown et al.
patent: 6680321 (2004-01-01), Roberts et al.
patent: 6696447 (2004-02-01), Brown et al.
patent: 6784181 (2004-08-01), Brown et al.
patent: 7030124 (2006-04-01), Chang et al.
patent: 7229994 (2007-06-01), Brown et al.
patent: 7253173 (2007-08-01), Brown et al.
patent: 2004/0138228 (2004-07-01), Roberts et al.
patent: 2006/0030569 (2006-02-01), Brown et al.
patent: 2006/0142296 (2006-06-01), Brown et al.
patent: 2006/0167004 (2006-07-01), Brown et al.
patent: 2007/0249619 (2007-10-01), Brown et al.
patent: 2007/0270435 (2007-11-01), Brown et al.
patent: 2007/0293502 (2007-12-01), Brown et al.
patent: 2009/0291966 (2009-11-01), Frey et al.
patent: 2010/0168130 (2010-07-01), Brown et al.
patent: 2431178 (1975-01-01), None
patent: 2900810 (1980-07-01), None
patent: 0133323 (1985-02-01), None
patent: 0166302 (1986-01-01), None
patent: 0283310 (1988-09-01), None
patent: 0289227 (1988-11-01), None
patent: 0624584 (1998-08-01), None
patent: 2696744 (1994-04-01), None
patent: 2076403 (1981-12-01), None
patent: 2210366 (1989-06-01), None
patent: 215847 (1999-04-01), None
patent: 217619 (2000-03-01), None
patent: 7138230 (1995-05-01), None
patent: 8604584 (1986-08-01), None
patent: 9107967 (1991-06-01), None
patent: 9204338 (1992-03-01), None
patent: 9206971 (1992-04-01), None
patent: 9315062 (1993-08-01), None
patent: 9504051 (1995-02-01), None
patent: 9626196 (1996-08-01), None
patent: 9723466 (1997-07-01), None
patent: 9828270 (1998-07-01), None
patent: 9828275 (1998-07-01), None
patent: 9901033 (1999-01-01), None
patent: 9933806 (1999-07-01), None
patent: 0001375 (2000-01-01), None
patent: 0145637 (2001-06-01), None
patent: 0146174 (2001-06-01), None
patent: 0146263 (2001-06-01), None
patent: 0174805 (2001-10-01), None
patent: 02094786 (2002-11-01), None
patent: 02094794 (2002-11-01), None
patent: 02094812 (2002-11-01), None
patent: 03029215 (2003-04-01), None
patent: 03094853 (2003-11-01), None
patent: 2004041800 (2004-05-01), None
patent: 2004041801 (2004-05-01), None
patent: 2004041802 (2004-05-01), None
patent: 2004062562 (2004-07-01), None
patent: 2005066148 (2005-07-01), None
patent: 2006014133 (2006-02-01), None
patent: 2006091160 (2006-08-01), None
Jones et al, “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.” Gut 2000, (Suppl II)47:ii1-ii19.
Adriaensen, H. et al., “Clinical Review of Oral Drug Treatments for Diabetic Neuropathic Pain-Clinical Outcomes Based on Efficacy and Safety Data from Placebo-Controlled and Direct Comparative Studies,” Diabetes Metab. Res. Rev., 2005, 21(3), pp. 231-240.
Banker, G. et al., “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Bilsky, E. et al., “SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist,” Journal of Pharmacology and Experimental Therapeutics, 1995, vol. 273, pp. 359-366.
Bilsky, E. et al., “Characterization of Enantiomers of (+)BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists,” Regulatory Peptides, 1994, vol. 54, pp. 25-26.
Burkey, T. et al., “The Efficacy of Delta-Opioid Receptor-Selective Drugs,” Life Sciences, 1998, vol. 62, Nos. 17/18, pp. 1531-1536.
Calderon, S. et al., “Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(R)-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide Delta Opioid Receptor Agonist,” J. Med. Chem., 1994, vol. 37, pp. 2125-2128.
Calderon, S. et al., “Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis, Opioid Receptor Binding, and Bioassay of the Highly Selective Delta Agonist (+)-4-[(R)-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyI)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and Related Novel Nonpeptide Delta Opioid Receptor Ligands,” J. Med. Chem., 1997, vol. 40, pp. 695-704.
Chang, K. et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” The Journal of Pharmacology and Experimental Therapeutics, 1993, vol. 267, No. 2, pp. 852-857.
Davis, MP et al., “Controversies in Pharmacotherapy of Pain Management,” Lancet Oncol., 2005, 6(9), pp. 696-704.
Filliol, D. et al., “Mice deficient for delta- and mu-opioid receptors exhibit opposing alternations of emotional responses,” Nature Genetics, 2000, vol. 25, pp. 195-200.
Greene, T. et al., “Protective Groups in Organic Synthesis,” 1981, pp. 267-268 and 331.
Katrizky, A. et al., “Benzotriazole-mediated Arylalkylation and Heteroarylalkylation,” Chemical Society Reviews, 1994, pp. 363-373.
Kingsbury, W. et al., “Synthesis of Structural Analogs of Leukotriene B4 and Their Receptor Binding Activity,” J. Med. Chem., 1993, vol. 36, pp. 3308-3320.
Lopez, J. et al., “Exploring the Structure-Activity Relationships of [1-(4-tert-Butyl-3′-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a High-Affinity and Selective Delta Opioid Receptor Nonpeptide Agonist Ligand,” J. Med. Chem., 1999, vol. 42, pp. 5359-5368.
Nagase, H. et al., “The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (-31 ) TAN-67 on Pain Modulation,” Life Sciences, 2001, vol. 68, pp. 2227-2231.
Nortey, S. et al., “Piperazinyl Benzamidines: Synthesis and Affinity for the Delta Opioid Receptor,” Bioorganic & Medicinal Chemistry Letters, 2001, vol. 11, pp. 1741-1743.
Plobeck, N. et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Delta Opioid Receptor Agonists with Increased in Vitro Metabolic Stability,” J. Med. Chem., 2000, vol. 43, pp. 3878-3894.
Przewlocki, R. et al., “Opioids in Neuropathic Pain,” Curr. Pharm. Des. 2005, 11(23), pp. 3013-3025.
Saitoh, A., “Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavorial models in rodents,” J. Pharmacol. Sci., 2004, vol. 95, pp. 374-380.
Snyder, S. et al., “Historical Review: Opioid Receptors,” TRENDS in Pharmacological Sciences, 2003, vol. 24, pp. 198-205.
Suggs, J. et al., “Facile Synthesis of 8-Substituted Quinolines,” J. Org. Chem., 1980, vol. 45, pp. 1514-1515.
Takemori, A. et al., “Selective Natrexone-Derived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol., 1992, vol. 32, pp. 239-269.
Vippagunta, S. et al., “Crystalline Solids,” Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
West, A., “Solid State Chemistry and its Applications,” Wiley, New York, 1988, pp. 358 & 365.
Wolff, M., “Burger's Medicinal Chemistry and Drug Discovery, 5ed, Part 1,” John Wiley & Sons, 1995, pp. 975-977.
Zhang, X. et al., “Probes for Narcotic Receptor Mediated Phenomena. 26.1-3 Synthesis and Biological Evaluation of Diarylmethylpiperazines and Diarylmethylpiperidines as Novel, Nonpeptidic Delta Opioid Receptor Ligands,” J. Med. Chem., 1999, vol. 42, pp. 5455-5463.
International Search Report issued for PCT/SE02/00956 on Sep. 18, 2002.
Non-final Office Action issued for U.S. Appl. No. 10/714,447 on Sep. 10, 2004.
Final Office Action issued for U.S. Appl. No. 10/714,447 on Mar. 22, 2005.
Advisory Action
Brown William
Griffin Andrew
Jones Paul
Page Daniel
Plobeck Niklas
Astrazeneca AB
Moore Susanna
Woodcock & Washburn LLP
LandOfFree
4(phenyl-piperazinyl-methyl) benzamide derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4(phenyl-piperazinyl-methyl) benzamide derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4(phenyl-piperazinyl-methyl) benzamide derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2624328